{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:03Z","timestamp":1747181163530,"version":"3.40.5"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:p>Patients with type 2 diabetes mellitus are frequently hospitalized for heart failure. The ratio of early diastolic mitral inflow velocity to early diastolic mitral annulus velocity (E\/e\u2019), measured by echocardiography, is a simple and convenient indicator of diastolic dysfunction. Various large clinical trials have reported that sodium glucose transporter-2 inhibitor therapy reduced cardiovascular events and hospitalizations in heart failure patients. We examined the effect of tofogliflozin on various physiological and cardiac function. A retrospective analysis was performed on elderly patients aged 65 years or older with type 2 diabetes mellitus attending Himi Municipal Hospital who were taking oral tofogliflozin 20\u2009mg\/day. Measurement of physiological and hormonal variables, blood sampling, and echocardiographic evaluations at 0, 1, 3, and 6 months were performed on those with ejection fraction (EF) of 40% or greater at the time of treatment. Statistical analysis was performed using <jats:italic toggle=\"yes\">t<\/jats:italic>-tests and mixed-effects models, with brain natriuretic peptide less than or not less than 100 pg\/mL, estimated glomerular filtration rate (eGFR) less than or not less than 50\u2009mL\/min\/1.73 m<jats:sup>2<\/jats:sup>, and diuretics administered or not. Hypoglycemic effects were observed at 0, 1, 3, and 6 months. At each time point, EF was retained and E\/e\u2019 was significantly reduced. On the other hand, most physiological parameters and laboratory results showed no clinical abnormalities. Mixed-effects models showed time-dependent reduction of E\/e\u2019 in high\/low brain natriuretic peptide, high\/low eGFR, with or without diuretics between baseline and at 6 months. The interaction with time was significant in high\/low eGFR. Tofogliflozin was shown to improve E\/e\u2019, a measure of diastolic function, while maintaining EF, with hypoglycemic effects and no clinical side effects.<\/jats:p>","DOI":"10.1097\/md.0000000000038948","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T18:38:43Z","timestamp":1723228723000},"page":"e38948","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effects of 6-month administration of tofogliflozin on cardiac function in elderly patients with heart failure with preserved ejection fraction: A retrospective study of a patient cohort"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8690-5473","authenticated-orcid":false,"given":"Toshihiro","family":"Higashikawa","sequence":"first","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"},{"name":"Department of Geriatric Medicine, Kanazawa Medical University, Uchinada, Kahoku-gun, Ishikawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"},{"name":"Mizuno Clinic, Chiyodadaicho 6-1, Kawachinagano, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichirou","family":"Ishigami","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Kuroki","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Yamada","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusho","family":"Sangen","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kiyosawa","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Saito","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nakahashi","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Kanazawa Medical University, Uchinada, Kahoku-gun, Ishikawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kasamaki","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsugiyasu","family":"Kanda","sequence":"additional","affiliation":[{"name":"Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Okuro","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Kanazawa Medical University, Uchinada, Kahoku-gun, Ishikawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study.","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial.","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-022-01508-6","article-title":"Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.","volume":"21","author":"Suzuki","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"H813","DOI":"10.1152\/ajpheart.00602.2015","article-title":"Sex differences in clinical characteristics and long-term outcome in acute decompensated heart failure patients with preserved and reduced ejection fraction.","volume":"310","author":"Nakada","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R8-20250503","first-page":"242","article-title":"Gender disparities in heart failure with mid-range and preserved ejection fraction: results from APOLLON study.","volume":"21","author":"\u00d6zlek","year":"2019","journal-title":"Anatol J Cardiol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.jacc.2017.01.058","article-title":"Estimating left ventricular filling pressure by echocardiography.","volume":"69","author":"Andersen","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/01.CIR.102.15.1788","article-title":"Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study.","volume":"102","author":"Ommen","year":"2000","journal-title":"Circulation"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-020-01175-5","article-title":"Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.","volume":"20","author":"Rau","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.","volume":"17","author":"Soga","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"165","DOI":"10.14740\/jocmr4098","article-title":"Effects of tofogliflozin on cardiac function in elderly patients with diabetes mellitus.","volume":"12","author":"Higashikawa","year":"2020","journal-title":"J Clin Med Res"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"530","DOI":"10.14740\/jocmr4278","article-title":"Gender differences in cardiac function following three-month administration of tofogliflozin in patients with diabetes mellitus.","volume":"12","author":"Higashikawa","year":"2020","journal-title":"J Clin Med Res"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/jdi.13122","article-title":"Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: a pilot study.","volume":"11","author":"Tochiya","year":"2020","journal-title":"J Diabetes Investig"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10557-019-06892-y","article-title":"Effect of tofogliflozin on systolic and diastolic cardiac function in type 2 diabetic patients.","volume":"33","author":"Otagaki","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"106243","DOI":"10.1016\/j.phrs.2022.106243","article-title":"The impact of SGLT2 inhibition on imaging markers of cardiac function: a systematic review and meta-analysis.","volume":"180","author":"Theofilis","year":"2022","journal-title":"Pharmacol Res"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics.","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control.","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12933-023-01879-4","article-title":"Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial.","volume":"22","author":"Katakami","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/hr.2011.169","article-title":"Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension.","volume":"35","author":"Ito","year":"2012","journal-title":"Hypertens Res"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"e11942","DOI":"10.1097\/MD.0000000000011942","article-title":"Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.","volume":"97","author":"Li","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/nep.13552","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: a comparison study with furosemide and tolvaptan.","volume":"24","author":"Ohara","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure.","volume":"115","author":"Guder","year":"2007","journal-title":"Circulation"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"e27638","DOI":"10.1097\/MD.0000000000027638","article-title":"Effects of tofogliflozin on adrenocorticotropic hormone, renin and aldosterone, and cortisol levels in elderly patients with diabetes mellitus: a retrospective study of a patient cohort.","volume":"100","author":"Higashikawa","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"19603","DOI":"10.1038\/s41598-022-24280-9","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.","volume":"12","author":"Manosroi","year":"2022","journal-title":"Sci Rep"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.2147\/DMSO.S223629","article-title":"Dynamics of epicardiac fat and heart function in type 2 diabetic patients initiated with SGLT-2 inhibitors.","volume":"12","author":"Braha","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial.","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1161\/CIRCULATIONAHA.109.884866","article-title":"B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies.","volume":"120","author":"Di Angelantonio","year":"2009","journal-title":"Circulation"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:38:13Z","timestamp":1746319093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":34,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038948","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,8,9]]}}}